Last reviewed · How we verify
AZD6765 iv
AZD6765 is an NMDA receptor antagonist that modulates glutamatergic neurotransmission to produce rapid-acting antidepressant effects.
AZD6765 is an NMDA receptor antagonist that modulates glutamatergic neurotransmission to produce rapid-acting antidepressant effects. Used for Major depressive disorder (treatment-resistant depression).
At a glance
| Generic name | AZD6765 iv |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
AZD6765 blocks NMDA receptors, which are ionotropic glutamate receptors involved in excitatory neurotransmission. By antagonizing these receptors, the drug is thought to rapidly alleviate depressive symptoms through downstream effects on synaptic plasticity and neuronal signaling. This mechanism is similar to ketamine, a known rapid-acting antidepressant, but AZD6765 was designed as a potentially safer alternative with a different pharmacokinetic profile.
Approved indications
- Major depressive disorder (treatment-resistant depression)
Common side effects
- Dissociation
- Dizziness
- Nausea
- Headache
Key clinical trials
- A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder (PHASE2)
- This is a Study to Determine the Antidepressant Effects of AZD6765 (PHASE2)
- AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) (PHASE1)
- A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels (PHASE1)
- AZD6765 Severe Major Depressive Disorder (MDD) IV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |